Scientists from Brown University (USA) found that taking the glucose-lowering drug metformin can reduce the risk of developing malignant tumors on the skin surface. Research results It was published In the Journal of Medicine in Dermatology.
More than eight thousand patients with basal cell skin cancer, approximately 4,100 volunteers with squamous cell carcinoma, and a group of more than eight thousand healthy people participated in the study.
Data from each skin cancer patient was compared with information from four healthy people of the same age, race, ethnicity and gender. The results showed that the risk of developing malignant skin epithelioma was significantly reduced in participants of European descent who took metformin.
Metformin did not show a protective effect in black patients with squamous cell carcinoma. Researchers believe this discrepancy may be because cancer in these patients often develops in areas of skin not exposed to sunlight and is associated with chronic scarring and inflammation that may not be affected by metformin.
Scientists suggest that metformin may have a protective effect by regulating mechanisms that prevent cancer cells from accessing energy and nutrients. The drug can also suppress the ability of malignant cells to grow and multiply. The drug promotes the death of defective cells, strengthens the immune response against cancer cells, reduces inflammation and prevents the formation of new blood vessels in skin tumors.
Scientists suggested that further research may support the use of metformin as a chemopreventive agent to prevent skin cancer.
Previously was named the main provocateur of diabetes and heart disease.
What are you thinking?
Source: Gazeta

Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.